Enlivex Raises $21M Debt for RAIN Token Expansion

Enlivex Therapeutics Ltd., a Nasdaq-listed biotechnology company developing immunotherapies for inflammatory conditions, announced on Tuesday that it has raised $21 million through a debt financing agreement to expand its holdings in RAIN tokens, the native asset of the decentralized prediction market platform Rain Protocol.

The company exercised an option to acquire more than three billion RAIN tokens for $10 million at a price of $0.0033 per token, securing a 62 percent discount compared to prevailing market rates. Enlivex also extended its rights to purchase an additional 272 billion RAIN tokens at the same price, with the options valid through December 2027. The financing came from New York-based asset manager The Lind Partners in the form of a convertible note, yielding approximately $18.7 million in net proceeds after costs. The note features a fixed conversion price of $2.69175 per share, a premium to recent trading levels.

Enlivex Executive Chairman Shai Novik described the move as part of the company's ongoing strategy. "We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, allowing us...